<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909037</url>
  </required_header>
  <id_info>
    <org_study_id>TILFLEXFY 002</org_study_id>
    <nct_id>NCT01909037</nct_id>
  </id_info>
  <brief_title>Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis</brief_title>
  <official_title>Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tilman S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bioxtract SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tilman S.A.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of bio-optimized curcumin(Flexofytol)&#xD;
      during a 90-days period in knee ostearthritis patients on the serum levels of specific&#xD;
      biomarkers of osteoarthritis and on the evaluation of pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of biomarkers of cartilage metabolism and inflammation</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline of serum levels of biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and the global patient assessment of disease activity using a Visual Analog Scale (VAS)</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline of the mean pain over the last 24 hours and of the global assessment of disease activity by the patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Flexofytol (bio-optimized curcumin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flexofytol (bio-optimized curcumin)</intervention_name>
    <description>2x3 caps/day (before breakfast and in the evening) for 3 months</description>
    <arm_group_label>Flexofytol (bio-optimized curcumin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  45 to 80 years of age&#xD;
&#xD;
          -  Internal femorotibial gonarthrosis responding to the clinical and radiological&#xD;
             criteria of ACR&#xD;
&#xD;
          -  Symptomatic knee for more than 6 months&#xD;
&#xD;
          -  Mean knee pain on the last 24 hours of at least 40 mm on VAS&#xD;
&#xD;
          -  Kellgren &amp; Laurence grade II to III&#xD;
&#xD;
          -  Patients able to avoid NSAIDs and analgesics during the study&#xD;
&#xD;
          -  Patients having signed informed consent&#xD;
&#xD;
          -  Patients able to follow the study instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Related to the osteoarthritis pathology:&#xD;
&#xD;
               -  Osteoarthritis linked to a metabolic arthropathy&#xD;
&#xD;
               -  Predominant associated symptomatic femoropatellar osteoarthritis&#xD;
&#xD;
               -  Chondromatosis or villonodular synovitis of the knee&#xD;
&#xD;
               -  Recent trauma (&lt; 1 month) of the knee responsible for the pain&#xD;
&#xD;
               -  Inflammatory flare&#xD;
&#xD;
               -  Pathology potentially interfering with the evaluation (metabolic inflammatory&#xD;
                  arthropathy, rheumatoid arthritis, lower limb radiculalgia, arthritis...&#xD;
&#xD;
               -  Paget disease&#xD;
&#xD;
               -  Homolateral coxarthrosis&#xD;
&#xD;
               -  Articular Prosthesis&#xD;
&#xD;
               -  Knee joint effusion&#xD;
&#xD;
          -  Related to previous and associated treatments:&#xD;
&#xD;
               -  Corticosteroids injection in the previous month, whatever the joint concerned,&#xD;
&#xD;
               -  Hyaluronan injection in the evaluated knee during the previous 6 months,&#xD;
&#xD;
               -  NSAID or analgesics in the 72 hours prior to inclusion&#xD;
&#xD;
               -  No modification of Slow-acting drugs for OA and/or dietary supplements taken&#xD;
                  within less than 6 months prior to the study(ex: chondroitin sulfate, diacerein,&#xD;
                  soy and avocado unsaponifiables, oxaceprol, granions de cuivre, glucosamine,&#xD;
                  phytotherapy for OA, homeopathy for OA...),&#xD;
&#xD;
               -  Anticoagulant (coumarinic) treatment and heparin&#xD;
&#xD;
               -  General corticotherapy,&#xD;
&#xD;
               -  Contraindication to paracetamol.&#xD;
&#xD;
          -  Related to associated pathologies:&#xD;
&#xD;
               -  Patient suffering from serious associated illness (liver failure, kidney failure,&#xD;
                  non-controlled cardiovascular diseases...)&#xD;
&#xD;
          -  Related to patients:&#xD;
&#xD;
               -  Pregnant or breastfeeding women&#xD;
&#xD;
               -  Pre-menopausal women with no contraception&#xD;
&#xD;
               -  Patients unable to write&#xD;
&#xD;
               -  Patients enrolled in a clinical trial in the previous 3 months&#xD;
&#xD;
               -  Patients under juristic protection or under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Castermans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citadelle Hospital of Liege</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvan Dierckxsens</last_name>
    <role>Study Director</role>
    <affiliation>Tilman S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Citadelle Hospital</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>curcumin</keyword>
  <keyword>biomarker</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

